The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
| VGSLX | |
| Total Expense Ratio | 0.13 |
| Annual Report Gross Expense Ratio | 0.13 |
| Fund Existence | 24 years |
| Gain YTD | 5.500 |
| Front Load | N/A |
| Min. Initial Investment | 3000 |
| Min. Initial Investment IRA | N/A |
| Net Assets | 64B |
| Annual Yield % from dividends | 3.86 |
| Returns for 1 year | -3.18 |
| Returns for 3 years | 18.09 |
| Returns for 5 years | 31.11 |
| Returns for 10 years | 63.23 |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AZTD | 28.44 | N/A | N/A |
| Aztlan Global Stock Sel Dm SMID ETF | |||
| SPEM | 47.02 | -0.01 | -0.02% |
| SPDR® Portfolio Emerging Markets ETF | |||
| XMAR | 39.62 | -0.02 | -0.04% |
| FT Vest U.S. Eq Enh & ModBufETF-Mar | |||
| CARY | 20.91 | -0.03 | -0.13% |
| Angel Oak Income ETF | |||
| THNR | 25.43 | -0.79 | -3.00% |
| Amplify Weight Loss Drug & Treatment ETF | |||